This could be the beginning of a new molecular era for the diagnosis of infectious diseases. Biological chips (biochips or microarrays and labchips) offer a potentially important shortcut to early diagnosis and treatment. It is also possible to develop multiplex assays for use in complex diagnostic situations; however, this technology depends crucially on the robotics developed to support these functions, and the soundness of the mathematics employed to analyse the output. Although the number of research applications is increasing, the question as to when, or if, chip-mediated techniques will be used routinely in the infectious disease clinic remains unanswered at present.
Several types of biological chips (microarrays) [1] are potentially useful for the study of microbial infections, and various numerical procedures (e.g., data mining and data-warehouse robotic methods) exist for analysing the numerical results obtained. Microarrays can be designed by the user, and some commercial kits are also now available (e.g., http://www.affymetrix.com; http://www.sequenom.com).
Two types of biological chip can be used in clinical microbiology: first, microarrays [2] or biochips, which are biological microchips used for diagnostics or research concerning new drugs or their targets (pharmacogenomics) [3] ; and second, labchips, which are useful as a multipletest diagnostic tool (http://www.agilent.com), especially for 'point-of-care testing'. This latter term refers to diagnostic tests performed outside the laboratory in the immediate proximity of patients (whether hospitalised or not), and such tests may be particularly useful in emergency situations, disasters and when investigating outbreaks.
Biochips can be elaborated by different procedures, but the most common are photolithography (as for informatics chips) and spectrophotometric detection. Biochips can be used to develop multiplexed assays [4] for use in complex situations, and are thus elegant tools for difficult situations where a non-conventional mathematical approach is in order (i.e., they provide easy solutions for complex problems). Labchips are 'nanolaboratories', in that they use nanotechnology to perform PCR, chromatography, electrophoresis and other techniques, all on a single chip. A single labchip can be used to perform several investigations on a single sample simultaneously. Some labchips allow multiplexed systems, so that several techniques can be used simultaneously with several samples on a single chip.
The use of biochips (microarrays) involves a number of different steps that have been described in detail elsewhere [1] [2] [3] [4] , but the sample to be analysed is usually prepared by PCR and labelled with a fluorescent (occasionally chemiluminescent or radioactive) molecule. Following hybridisation with the chip, the results obtained are normally revealed with the aid of a laser beam, scanned, and compared with genetic databases. Similarities in the databases are determined by data mining systems [5] , and the results are expressed as a percentage. In our own laboratory, the data are transferred, following validation, into the database of a genetic laboratory information management system by a data-warehouse procedure. Such methods are based on different types of cluster analysis (Table 1 ) [6] . Results are conserved for future analysis using software that updates the database continuously. However, the clustering method used may not always be the same, and the selection of a clustering procedure should be done by an expert in applied mathematics. Similarly, the breakpoint in 'cut-off' studies must be determined according to epidemiological definitions derived from previous large conventional studies. The robotics used to support these functions usually depend on fuzzy logic [7] , and the tools required are variable, again requiring the advice of experts in this field. The most common approaches are genetic algorithms and neural networks, but any method used in artificial intelligence [8] can be applied.
Microarrays have already been used to investigate genetic expression and polymorphisms in certain microorganisms, such as Mycobacterium tuberculosis, Escherichia coli, Staphylococcus aureus and Helicobacter pylori, not only in the context of historical epidemiological research, but also as a rapid diagnostic method for use with critically ill patients or in the case of possible outbreaks of infection. Drug-induced alterations in gene expression have been studied with Streptococcus pneumoniae and industrial yeasts [9] , and the pathogenesis of infection is a frequent topic of microarray-related research in the recent literature [10] [11] [12] . In M. tuberculosis, investigations of the effect of isoniazid on gene expression [13] and gene-mapping studies [14] have been performed with microarrays. Biochips have been used to determine antimicrobial resistance in Strep. pneumoniae [15] , and to investigate the genetic divergence and fitness of sub-clones of H. pylori [16] .
Microarrays have also been used in the design of vaccines [17] , for serodiagnostics [18, 19] , research into genetic targets for drugs [20] , study and control of parasites [21, 22] , diagnosis and treatment of viral infections [23] and the development of new antimicrobials. An algorithm used for diagnostics [24] must be modified continuously because DNA is a structure that evolves constantly. It must also be emphasised that this technology is crucially dependent upon the soundness of the mathematics employed. This is the beginning of a new molecular era for the diagnosis and treatment of infectious diseases, and biological chips (http://www.lab-on-a-chip. com) constitute a very important potential shortcut to early diagnosis and treatment. Biological chips seem to have an expanding future, but not without some obvious drawbacks ( Table 2) . However, there are two main reasons why the possible introduction of these techniques into the clinical microbiology laboratory should be investigated: first, the desire of clinicians to increase the quality of care for patients; and second, the potential benefits for health care management in general, in terms of economics and in the general context of quality assurance and efficient resolution of health care problems. The current challenge is to establish the criteria for development of the necessary equipment and intelligent software. Cost may or may not be the most important problem, depending on local circumstances, but it will be necessary to standardise the technical components of the system and establish appropriate technical support and quality management arrangements. Perhaps the most important limiting factor is the shortage of qualified personnel, especially experts in the mathematical models involved in these techniques. Although the 
